Zook outlined NeoGenomics’ broad menu of over 500 oncology-focused tests and identified therapy selection and MRD markets as representing “more than $40 billion of addressable market opportunity.” He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback